In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug

PCC0104005 is a novel drug candidate for treating schizophrenia that displays high affinity for serotonin, dopamine, and noradrenaline receptors, including partial agonism at dopamine D(2), D(3), D(4), serotonin 5-HT(1A), and 5-HT(2A) receptors and antagonism at 5-HT(2B), 5-HT(6), and 5-HT(7) recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yanan, Zhu, Xiaoyin, Wang, Hongbo, Sun, Shanyue, Yue, Xin, Tian, Jingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931996/
https://www.ncbi.nlm.nih.gov/pubmed/29720711
http://dx.doi.org/10.1038/s41598-018-25036-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931996/
https://www.ncbi.nlm.nih.gov/pubmed/29720711
http://dx.doi.org/10.1038/s41598-018-25036-0

Ejemplares similares